Finished Pharmaceuticals: Current Good Manufacturing Practice

Part 211 concerns finished pharmaceuticals, including specified preparations before clinical dispensing. Part 210 explains applicability and the relationship with other regulations. Biological products, radiopharmaceuticals and investigational manufacture can involve additional or different provisions. A site assessment should identify each activity and dosage form rather than assuming that a general drug registration defines its full CGMP obligations. FDA regulatory overview.

The quality control unit has responsibilities for approving or rejecting components, containers, closures, in-process materials, packaging, labeling and drug products. Written procedures govern its work. Its authority must operate in purchasing, production and disposition decisions; a title on an organization chart cannot compensate for release decisions made without the required quality review. Part 211.

Production and process-control procedures address the operations needed to assure consistent quality. Equipment maintenance, cleaning, material identification and control of contamination affect product quality before a final sample reaches the laboratory. FDA’s CGMP questions and answers explain how the agency interprets recurring technical issues; those explanations should be read with the cited requirements. FDA CGMP questions.

Specifications, scientifically sound laboratory controls and appropriate testing support acceptance decisions. Stability testing establishes suitable storage conditions and expiration dating under the applicable provisions. An unexplained laboratory result cannot be replaced by repeated testing until a favorable result appears. The investigation must examine the evidence and its implications for the batch and related production. Laboratory provisions.

Master and batch production records connect instructions with actual manufacture. Records review, investigations, distribution records, complaint handling and returned-product controls provide evidence after production. FDA publishes questions on these systems because weaknesses often span several departments. Contract work also requires clear responsibilities and access to the information needed for quality decisions. FDA CGMP resources.

Identify the governing parts, map responsibilities and compare the operating procedures with actual records. Use FDA technical questions to investigate relevant gaps, not as a checklist that proves universal compliance. Passing a product test or holding a third-party quality certificate does not replace CGMP implementation or the applicable marketing authorization. FDA regulatory context.